Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IY-HCR21 vs IY-MIC in Healthy Volunteers
NCT06471868Phase 1Active, not recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bethanechol in urinary retention (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoints: Area Under the Concentration-time Curve at Steady State at Day 3 and Maximum Plasma Concentration at Steady State at Day 3. Started Jun 2024; status: active, not recruiting.
02
Drugs
bethanechol
03
Conditions
urinary retention
Beyond the preview
Go deeper on NCT06471868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471868.